true

Vascular access and medication delivery COVID-19 response efforts

Background Image
Overview
quote-icon
Emerging stronger, together

For the healthcare community. For patients. For all.

We are all working together toward one goal in health while navigating the uncertainty of COVID-19. Rest assured that BD is committed to helping you determine the best solutions across the continuum of care now and in the future as needs surrounding the pandemic continue to evolve.

The Impact of COVID-19 on Healthcare
  • The average hospital length of stay (LOS) in the U.S. is 5.5 days1, while the median LOS of COVID-19 survivors is 10 to 13 days2

    The average hospital length of stay (LOS) in the U.S. is 5.5 days1, while the median LOS of COVID-19 survivors is 10 to 13 days2

  • Almost 15% of patients hospitalized with COVID-19 required renal replacement therapy (RRT)3

  • The U.S. government has purchased sufficient COVID-19 vaccine doses to vaccinate 300 million people4

    The U.S. government has purchased sufficient COVID-19 vaccine doses to vaccinate 300 million people4

KEY CHALLENGES

Treating COVID-19 Patients is Complex—We can Help

Key challenges your facility may be facing

COVID-19 vaccination preparedness

As COVID-19 vaccinations accelerate and researchers continue pursuing novel vaccines and treatments, BD is responding with a full suite of medication delivery devices to meet the needs of each potential drug. We are continuing to work with the U.S. government to understand needs, scaling up production and ensuring supply availability for safe administration of vaccines.

Learn More

Selecting the most appropriate device to extend dwell time and reduce catheter restarts

Helping to reduce complications

Minimizing patient and clinician exposure

Manufacturing and logistics have been amplified to ensure continuous product availability

We are:

  • Mobilizing manufacturing workforce to maintain production and availability of products.
  • Increasing production of critical supplies and ongoing investments in global manufacturing capacities to strengthen inventory
  • Closely monitoring inventory and customer ordering, and placing critical products on manual inventory allocation, to ensure supply continuity


Learn More

Staff Training and Education Gaps
Advantages of the BD Nexiva™ Closed IV Catheter System
Infographic
Advantages of the BD Nexiva™ Closed IV Catheter System

The COVID-19 pandemic has heightened clinicians’ awareness of the potential risks of exposure to bloodborne pathogens when starting and managing peripheral IV catheters (PIVCs).

 

Download

Notes

* Compared to an open system

† Chlorhexidine gluconate

‡ Isopropyl alcohol

§ Compared to B. Braun Introcan Safety® Catheter with Bard Statlock® IV Ultra Stabilization Device

‖ The BD Max needle-free connector technology includes the BD MaxPlus™ Needle-free Connector and the BD MaxZero™ Needle-free Connector.

¶ For CVAD tip placement confirmation of approaches from the superior vena cava.

# When compared to traditional PICC placement methods of blind placement and chest X-ray (CXR).

** Company sponsored study comparing Sherlock 3CGTM TCS on adult patients against historical PICC placement standard of care for blind insertion by a CXR for tip confirmation. Data on file.

†† Reduced cost based on post-hoc exploratory analysis suggesting the costs between the two placement processes are different.

*** Comparison in relation to Bard PowerPICC™ Catheters

Reference
  1. Length of hospital stay (indicator). Organisation for Economic Cooperation and Development (OECD) iLibrary website. https://www.oecd-ilibrary.org/social-issues-migration-health/length-of-hospital-stay/indicator/english_8dda6b7a-en. Published 2019. Accessed July 27, 2020.
  2. Interim Clinical Guidance f¬or Management of Patients with Confirmed Coronavirus Disease (COVID-19). Centers for Disease Control and Prevention (CDC) website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Published 2020. Updated June 30, 2020. Accessed July 15, 2020.
  3. Acute kidney injury in patients hospitalized with COVID-19. Hirsch, Jamie S.Abate, Mersema et al. Kidney International, Volume 98, Issue 1, 209 - 218.
  4. Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna. February 2021. https://www.hhs.gov/about/news/2021/02/11/biden-administration-purchases-additional-doses-covid-19-vaccines-from-pfizer-and-moderna.html [online] Available at [Accessed 03 May 2021]. Accessed March 3, 2021.
  5. González López JL, Vilela AA, Fernández del Palacio E, Corral JO, Martí CB, Portal PH. Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. J Hosp Infect. 2014;86(2):117–126. doi:10.1016/j.jhin.2013.10.008.
  6. Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter stabilization systems. J Infus Nurs. 2010;33(6):371–384. doi:10.1097/NAN.0b013e3181f85be2.
  7. Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980–5. doi: 10.2106/JBJS.D.01977.
  8. Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery. J Bone Joint Surg Am. 2009;91(8):1949–53. doi: 10.2106/JBJS.H.00768
  9. Infusion Nurses Society. Infusion Therapy Standards of Practice. J Infus Nurs. 2021;44(1S):S1–224.
  10. The Joint Commission. Preventing Central Line–Associated Bloodstream Infections: A Global Challenge, a Global Perspective. Oak Brook, IL: Joint Commission Resources, May 2012.

Let’s talk about how to support your COVID-19 efforts

Receive emails about the latest BD webinars, trade shows, training opportunities and other invitation-only events

Subscription Form

BD-23877 (05/21)

Chat with us
Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
×